More Reforms Needed To Raise China Healthcare Quality: AmCham
This article was originally published in PharmAsia News
The China FDA needs to do more to reduce a piling up drug approval backlog, while other issues such as clinical trial reviews, incentives for R&D and pricing in China are all of concern to the pharma industry, the American Chamber of Commerce says in its latest white paper.
You may also be interested in...
Suzhou-based Innovent Bio becomes the fourth biotech from mainland China to go public in Hong Kong, and its strong first-day performance may have given the seemingly spooked market so far for such companies a shot of confidence.
A rapidly reforming policy and regulatory environment and a growing culture of innovation are encouraging capital and talent to pour into China, making it a question of when, rather than if, the payoffs will come for both consumers and investors.